<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802811</url>
  </required_header>
  <id_info>
    <org_study_id>SHR2150-I-103</org_study_id>
    <nct_id>NCT04802811</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics of Oral SHR2150 in Healthy Subjects With Single Dose of SHR2150 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety,&#xD;
      tolerability and pharmacokinetics, pharmacodynamics of SHR2150.&#xD;
&#xD;
      will consist of 50 healthy subjects, 5 groups. The purpose of this part is to explore the&#xD;
      safety, tolerability ,pharmacokinetics and pharmacodynamics of single doses of SHR2150&#xD;
      capsule in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of treatment-related adverse events as assessed by CTCAE v5.0.</measure>
    <time_frame>9 DAYS for Group A.B.C.D.E</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of SHR2150, , main metabolite and identified major metabolites in plasma ：[AUC0-last]</measure>
    <time_frame>Up to 96hours</time_frame>
    <description>The area under the concentration-time curve from time zero (pre-dose) to last time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of SHR2150, , main metabolite and identified major metabolites in plasma ： [AUC0-∞]</measure>
    <time_frame>Up to 96hours</time_frame>
    <description>The area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of SHR2150, , main metabolite and identified major metabolites in plasma ：[t1/2]</measure>
    <time_frame>Up to 96hours</time_frame>
    <description>Terminal Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of SHR2150, , main metabolite and identified major metabolites in plasma： [Tmax]</measure>
    <time_frame>Up to 96hours</time_frame>
    <description>Time to Maximum Observed Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of SHR2150, , main metabolite and identified major metabolites in plasma ： [Cmax]</measure>
    <time_frame>Up to 96hours</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of SHR2150, , main metabolite and identified major metabolites in plasma ： [CL/F]</measure>
    <time_frame>Up to 96hours</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of SHR2150, , main metabolite and identified major metabolites in plasma ： [Vz/F]</measure>
    <time_frame>Up to 96hours</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of SHR2150, , main metabolite and identified major metabolites in plasma ： [MRT]</measure>
    <time_frame>Up to 96hours</time_frame>
    <description>Mean retention time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Changes in Cytokines in Serum: interferon γ-inducible protein-10</measure>
    <time_frame>Up to 48hhours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Changes in Cytokines in Serum: Interferon-α</measure>
    <time_frame>Up to 48hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2150；Placebo</intervention_name>
    <description>Single dose；SHR2150-dose 1 or Placebo-dose 1</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2150；Placebo</intervention_name>
    <description>Single dose；SHR2150-dose 2 or Placebo-dose 2</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2150；Placebo</intervention_name>
    <description>Single dose；SHR2150-dose 3 or Placebo-dose 3</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2150；Placebo</intervention_name>
    <description>Single dose；SHR2150-dose 4 or Placebo-dose 4</description>
    <arm_group_label>Treatment group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2150；Placebo</intervention_name>
    <description>Single dose；SHR2150-dose 5 or Placebo-dose 5</description>
    <arm_group_label>Treatment group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. Aged 18~45.&#xD;
&#xD;
          3. Body weight ≥ 50 kg for male; ≥ 45 kg for female, body mass index (BMI) between 18 to&#xD;
             28 kg/m2 ( Including boundary value) .&#xD;
&#xD;
          4. Vital signs, physical examination, laboratory results are within normal range or&#xD;
             considered not clinically significant.&#xD;
&#xD;
          5. Female subjects (including partner) of childbearing potential must be using a&#xD;
             medically acceptable form of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently suffering from cardiovascular, liver, kidney, digestive, nervous, blood,&#xD;
             thyroid or mental diseases.&#xD;
&#xD;
          2. Have severe infection, severe trauma or major surgical operations within 3 months.&#xD;
             Plan to receive surgery during the trial and within two weeks after the end of the&#xD;
             trial..&#xD;
&#xD;
          3. 12-ECG test have clinical significant abnormality or the QT interval (QTc) &gt; 450&#xD;
             ms(male)/QTc)&gt; 460 ms(male) or&lt;300ms(female).&#xD;
&#xD;
          4. Screening for infectious diseases is positive (Including HBsAg, Anti-HCV, TPPA,&#xD;
             Anti-HIV)&#xD;
&#xD;
          5. Suspected allergy to any ingredient in the study drug.&#xD;
&#xD;
          6. Have any drug that inhibits or induces liver metabolism within 1 month.&#xD;
&#xD;
          7. Any condition or disease that affects the absorption, metabolism, and/or excretion of&#xD;
             the study drug judged by the investigator;&#xD;
&#xD;
          8. Treatment with immunosuppressant or interferon-containing drugs within 6 months of&#xD;
             study drug administration;&#xD;
&#xD;
          9. Participated in clinical trials of any drug or medical device within 3 months before&#xD;
             screening, or within 5 half-lives before screening;&#xD;
&#xD;
         10. Treatment with live(attenuated) vaccine within 2 months before taking the study drug&#xD;
             or during the study or within 1 months after administration;&#xD;
&#xD;
         11. Had donated blood or blood transfusion≥ 200 mL within 1 months before taking the study&#xD;
             drug or had donated blood or blood transfusion≥ 400 mL within 3 months prior to&#xD;
             screening;&#xD;
&#xD;
         12. The average daily smoking ≥ 5 cigarettes within three months; the average daily&#xD;
             alcohol intake in a month exceeds 15 g (15 g alcohol is equivalent to 450 mL beer or&#xD;
             150 mL wine or 50 mL low-alcohol);&#xD;
&#xD;
         13. Keep smoking, drinking alcohol or consuming caffeinated foods or beverages (more than&#xD;
             8 cups, 1 cup = 250 mL) 2 days before taking the study drug and during the study; and&#xD;
             those who have special dietary requirements and cannot follow the unified diet;&#xD;
&#xD;
         14. History of drug abuse , drug dependence or drug screening test is positive;&#xD;
&#xD;
         15. Pregnant or lactating women;&#xD;
&#xD;
         16. Other conditions that the investigator believes the subject is not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing youan Hospital,Capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

